V. Benea *, D. Mureșan **, Elisabeta-Otilia Benea ***, M. Popescu ****, Diaconu J.D. *****
* Dr. Vasile Benea, medic primar, cercetător științific gr. II, Centrul Dermatovenerologic, Spitalul Clinic de Dermatovenerologie “Scarlat Longhin” București
** Dr. Dumitru Mureșan, Medic primar, cercetător științific gr. I, consultant, Centrul Dermatovenerologic, Spitalul Clinic de Dermatovenerologie “Scarlat Longhin” București, membru al Academiei de Științe Medicate
*** Dr. Elisabeta-Otilia Benea, medic primar șef de secție de lucrări, Institutul de Boli Infecțioase “Matei Balș”, UMF “Carol Davila” București
**** Dr. Marin Popescu, medic primar, cercetător științific gr. II, Centrul Dermatovenerologic, Spitalul Clinic de Dermatoveneroolgie “Scarlat Longhin” București
***** Prof. univ. dr. Justin-Dumitru Diaconu, șeful Clinicii Universitare “Scarlat Longhin”, directorul Centrului Dermatoveneorlogic București
Abstract
Despite the many years during which the syphilis has been subjected to intense scientific scrutinity, both its natural history and the optimal therapeutic approach continue to defy precise description. More, in the last years, the HIV infection/AIDS has, to a certain extent, undermined the assumed validity of models of syphilis staging and of the understanding of the clinical and serological response to therapy. There are a series of questions that address the central and often ambiguous area of syphilis management: the dose of 2,4 million UI banzathine penicillin, the alternatives to benzathine penicillin, the adequate therapy of neurosyphilis, the approapriate therapy for the patients with syphilis and HIV infection, penicillin allergy, the criteria for the cure of syphilis and persistent infection.